Since the spring of 2020, due to the spread of a new, very virulent coronavirus, the planet has been going through an economic crisis of unknown intensity. For many months, it was announced that salvation would come from a miraculous vaccine that would allow a massive recovery of trade. So, it was with great relief that Pfizer and BioNTech announced in November 2020 the development of a vaccine based on a new technology called messenger RNA (mRNA). After a brief euphoria, the logistical reality caught up with many observers: how to efficiently organize a freeze or deep-freeze supply chain to ensure the vaccination of billions of people over the world?
Since the WHO announced in March 2020 a pandemic situation following the spread of COVID-19 (SARS-CoV-2), the world has been experiencing a crisis of a magnitude not seen since the WWII. Although the number of deaths is much lower than that caused , was welcomed. Very quickly, however, it became clear that the success of a large-scale vaccination required an effective logistical organization with a unique deep-freeze supply chain . The most critical element was the extremely low transport and storage temperature of about -70° C, when traditional vaccines are transported and stored at about -20° C.
